Wall Street may be completely mispricing $BNTX ahead of ASCO
The market still prices $BNTX like a collapsing COVID company. r/wallstreetbets r/biotech r/investing
But the company now looks more like an oncology war chest with one of the deepest pipelines in biotech.
Most people don’t realize, BioNTech currently has:
- ~€17B cash
- massive late-stage oncology expansion
- 25+ active clinical programs
- major Phase 2/3 catalysts approaching
- strong partnership with $BMY and $2bln payments until 2028
- 50% revenue & cost sharing with BMY
The huge event is ASCO on May 29th.
This is where BioNTech presents key lung cancer data for Pumitamig (BNT327), potentially competing against Merck’s Keytruda in NSCLC.
That’s not a niche market. Keytruda generates >$25B annually.
If BioNTech shows:
- superior response rates
- stronger progression-free survival
- manageable toxicity
…the entire valuation framework changes.
Right now the market is acting as if the oncology pipeline is worth almost nothing.
That disconnect feels extreme.
Bull case:
- institutional re-rating
- return toward price targets of $150+
- “COVID company” narrative dies
Bear case:
- oncology data disappoints
- stock revisits cash-floor valuation
Either way, ASCO feels like one of the biggest binary biotech catalysts this quarter.
Anyone else following this closely